What can be done for patients with cancer of the digestive tract in 2003? Guidelines of the Francophone Federation of Digestive Tract Cancerology - Part II;Que faire devant un cancer digestif en 2003? Recommandations de la Fédération Francophone de Cancérologie Digestive (FFCD) Seconde Partie

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 1, 2003, Pages 43-58

  Legoux, Jean Louis ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILIARY TRACT CANCER; DIGESTIVE SYSTEM CANCER; ENDOCRINE TUMOR; HUMAN; LIVER CELL CARCINOMA; NONHODGKIN LYMPHOMA; PANCREAS TUMOR; REVIEW;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AMPULLA OF VATER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; COMMON BILE DUCT NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; FOLLOW-UP STUDIES; GASTRINOMA; HUMANS; INSULINOMA; LIVER NEOPLASMS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; NEOPLASM METASTASIS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; STOMACH NEOPLASMS; TIME FACTORS;

EID: 0037274580     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs A et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-30.
2. Levy I, Greig PD, Gallinger S, Langer B, Sherman M. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg 2001;234:206-9.
3. Ganne-Carrié N, Mohand D, N'Kontchou G, Grando-Lemaire V. Trinchet JC. Diagnostic et traitement du carcinome hépatocellulaire chez les malades atteints de cirrhose. Gastroenterol Clin Biol 2002;26:73-77.
4. Chevret S, Trinchet JC, Mathieu D, Abou Rached A, Beaugrand M, Chastang C for the Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999;31:133-141.
5. The Cancer of the Liver Italian Program (CLIP) investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840-5.
6. Trinchet JC, Beaugrand M. Augmentation de l'incidence du carcinome hépatocellulaire dans les pays occidentaux. Quelles raisons et quelles conséquences? Gastroentérol Clin Biol 1999;23:1286-88.
7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
8. Chapoutot C, Perney P, Fabre D, Taourel P, Bruel JM, Larrey D, et al. Essaimage sur le trajet de ponction échoguidée de carcinomes hépatocellulaires. Etude de 150 malades. Gastroenterol Clin Biol 1999;23:652-6.
9. Llovet JM, Fuster J, Bruix J, Fore E, for the Barcelona Clinic Liver Cancer Group. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1334-40.
10. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-82.
11. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993;18:1121-6.
12. Livraghi T, Bolondi L, Buscarini L, Cottone M, Mazziotti A, Morabito A, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995;22: 522-6.
13. Pelletier G, Roche A, Ink O, Anciaux ML, Derby DS, Rougier P. et al. Randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4.
14. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, et al. Treatment of unresecable hepatocellular carcioma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129-34.
15. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 1995;332:1256-61.
16. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte JJ, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002;359:1734-9.
17. Lo CM, Ngam H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
18. Bronowicki JP, Vetter D, Dumas F, Boudjema K, Bader R, Weiss AM, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer 1994;74:16-24.
19. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MDC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-83.
20. Raoul JL, Guyader D, Bretagne JF, Duvauferrier F, Bourguet P, Behkechi D, et al. Randomized controlled trial for hepatocelliar carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782-7.
21. Lau WY, Leung TWT, Ho SKW, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797-801.
22. Lai CL, Wu PC, Chan GCB, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. Cancer 1988;62:479-83.
23. Boige V, Ducreux M, Rougier P. Cancers primitifs du foie: traitement médical du carcinome hépato-cellulaire. In: Rougier P, Ducreux M, Seitz JF, eds. Place de la chimiothérapie dans la stratégie thérapeutique des cancers digestifs. Paris: John Libbey Eurotext, 2001:169-86.
24. Martinez Cerezo FJ, Tomas A, Donoso TA, Enriquez J, Guarner C, Balanzo J, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702-6.
25. Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994;26:66-8.
26. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones. Hepatology 1995;21:1535-42.
27. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo controlled trial in 120 patients. Gastroenterology 1995;109:917-22.
28. CLIP Group. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998;352:17-20.
29. Riestra S, Rodriguez M, Delgado M, Suarez A, Gonzalez N, de la Mata M, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998;26: 200-3.
30. Liu CL, Fan ST, Oi-Lin O, Lo CM, Tung-Ping P, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastoenterol 2000;95:218-22.
31. Barbare JC, Milan C, Bouché O, Raoul JL, Bommelaer G, Rougier P, et al. Etude randomisée du tamoxifène dans le traitement palliatif du carcinome hépatocellulaire: résultats de l'essai FFCD-ANGH 94-03 (abstract). Gastroenterol Clin Biol 2002;26: A 129.
32. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-7.
33. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A multicenter randomized trial of anti-androgenic treatment (leuprorelin+flutamide+tamoxifen vs tamoxifen) in patients with unresectable hepatocellular carcinoma (abstract). Hepatology 1998; 28:249 A.
34. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-7.
35. Villa E, Ferretti I, Grottola A, Buttafoco P, DelBuono MG, Giannini F, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001;84:881-5.
36. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-91.
37. Reste-t'il une place pour la chimioembolisation artérielle hépatique dans le traitement du carcinome hépatocellulaire? Gastroenterol Clin Biol 1995;19:967-9.
38. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
39. Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resecable cholangiocarcinoma. Gut 1996;39: 852-5.
40. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998;9:653-6.
41. Taïeb J, Mitry E, Boige V, Artru P, Eznfis J, Lecomte T, et al. Optimization of 5 fluorouracil (5FU) cisplatin combination chemotherapy with a new schedule of leucovorin, 5 FU cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 2002;13:1192-6.
42. Micames CG, Jowell P, White R, Pawlson E, Randon Nelson R, Pappas T, et al. Lower incidence of peritoneal carcinomatosis in pancreatic cancer diagnosed with endoscoic unltrasound guided FNA compared with percutaneous FNA. Dig Dis Week San Francisco, 19-22 Mai 2002.
43. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Feneglio CJ, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928-37.
44. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
45. Klinkenbijl JHG, Sahmoud T, van Pel R. Couvreur ML, Veenhof CHN, Arnaud JP. Radiotherapy and 5-FU after curative resection for the cancer of the pancreas and peri-ampullary region: a phase III trial of the EORTC GITCCG (abstract). Eur J Cancer 1997;33:274a.
46. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L. Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 10;358:1576-85.
47. Dunn JA, Stocken DD, Almond J, Bakkevold KE, Jeekel J, Douglas HO, et al. Meta-analysis of adjuvant chemoradiotherapy and chemotherapy for resectable pancreatic cancer including the final results of the ESPAC-1 trial. Proc Am Soc Clin Oncol 2002: A564.
48. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J. et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6 000 rads) radiation alone, moderate dose radiation (4 000 rads + 5-fluorouracil), and high dose radiation + 5 fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-10.
49. Wagener DJTH, van Hoesel QGCM, Yap SH, Hoogenraad WJ, Wobbes Th, Strijk SP. Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer. Cancer Chemother Pharmacol 1989;25: 131-4.
50. Komaki R, Wadler S, Peters T, Byhardt RW, Order S, Gallagher MJ, et al. High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group Protocol 8801). Cancer 1992;69:2807-12.
51. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-5.
52. Carter SK, Comis RL. The integration of chemotherapy into a combined modality approach for cancer treatment. Cancer Treat Rev 1975;2:193-214.
53. Burris HA, Moore MJ, Andersen J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
54. Rougier P, Zarba JJ, Ducreux M, Basile M, Pignon JP, Mahjoubi M, et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993;4:333-6.
55. André T, Lotz JP, Bouleuc C, Azzouzi K, Houry S, Hannoun L, et al. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 1996;7:173-8.
56. Underhill CR, Highley MS, Parnis FX, Mason RC, Larvin M,. et al. Epirubicin (E), cisplatin (C) and infusional 5-FU (F), (ECF) an active regimen in pancreatic carcinoma (PC) (abstract). Proc Am Soc Clin Oncol 1996;15:203a.
57. Taïeb J, Lecomte T, Ezenfis J, Artru P, Mitry E, Boige V, et al. Chimiothérapie des adénocarcinomes du pancréas non résécables par 5-fluorouracile, acide folinique et cisplatine (LV5-FU2). Gastroenterol Clin Biol 2002;26:605-9.
58. Rougier Ph, Ducreux M, Douillard JY, Seitz JF, Bugat R, Bosset JF, et al. Adénocarcinomes pancréatiques avancés (CPA): essai randomisé comparant l'efficacité de l'association 5FU-Cisplatine (FUP) à celle du 5FU seul (résumé). Gastroenterol Clin Biol 1999;23:111A.
59. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia del l'Italia Meridionale. Cancer 2002;94:902-10.
60. Raymond E, Hanauske A, Faivre S, Izbicka E, Clark G, Rowinsky ED, et al. Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. Eur J Cancer. 1997;33:696-7.
61. Ellas D, Rougier P, Lasser P, Duvillard P, Venezia P, Schlumberger M, et al. Reductional major surgery and chemotherapy in multimetastatic apudomas. Ann Chir 1988;42:474-81.
62. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169:36-42.
63. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, et al. Results of liver transplantation in the treatment of metastatic neuroendocrines tumors. A 31-case French multicentric report. Ann Surg 1997;225:355-64.
64. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma. Transplantation 1998;66:1307-12.
65. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71:2624-30.
66. Skinazi F, Zins M, Menu Y, Bernades P, Ruszniewski P. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. Eur J Gastroenterol Hepatol 1996;8: 673-8.
67. Bengmark S, Ericsson M, Lunderquist A, Martensson H, Nobin A, Sako M. Temporary liver dearteriolization in patients with metastatic carcinoid disease. World J Surg 1982;6:46-53.
68. Eriksson BK, Larsson EG, Skogseid BM, Löfberg AM, Lörelius LE, Öberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293-301.
69. Moertel CG, Johnson CM, McKusick MA, Martin JK, Nagorney DM, Kvols LK, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
70. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
71. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
72. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979:85:593-6.
73. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72: 244-8.
74. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, et al. The antitumoral effect of the long-acting somatostatine analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95: 3276-81.
75. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996;38:430-8.
76. Faiss S, Riecken EO, Wiedenmann B. Prospective, randomizes multicenter trial on the antiproliferative effect of lanreotide, interferon alfa and the combination for therapy of metastatic neuroendocrine GEP tumors. Proc Am Soc Clin Oncol 2000, 1014 (abst).
77. Oberg K, Norheim I, Lind E, Alm G, Lundqvist G, Wide L, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: long term results. Cancer Treat Rep 1986;70:1297-304.
78. Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 1993;72: 3099-105.
79. Andersson T, Wilander E, Eriksson B, Lindgren PG, Oberg K. Effects of interferon on tumor tissue content in liver metastases of human carcinoid tumors. Cancer Res 1990;50:3413-5.
80. Andreyev HJN, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, et al. Phase II study of continuous infusion fluorouracil and interferon alpha-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 1995;13:1486-92.
81. Franck M, Kaydan U, Wied M, Sprenger A, Klose J, Arnold R. Long term outcome of patients with metastasized endocrine tumors treated with the combination of octreotide and alpha-interferon (abstract). Gastroenterology 1997;112:440A.
82. Altimari A, Badrinath K, Reisel H, Prinz RA. DTIC therapy in patients with malignant intraabdominal neuroendocrine tumors. Surgery 1987;102:1009-17.
83. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-5.
84. Ruskoné-Fourmestraux A, Lavergne A, Delmer A: les lymphomes gastro-intestinaux. Gastroenterol clin biol 2002,26,231-49.
85. Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, et al. Cure of helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997;89:1350-5.
86. Ruskone-Fourmestraux A, Aegerter P, Delmer A, Brousse N, Galian A, Rambaud JC. Primary digestive tract lymphoma: a prospective multicentric study of 91 patients. Gastroenterology 1993;105:1662-71.
87. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998:16:1916-21.
88. Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2424-9.
89. Gobbi PG, Dionigi P, Barbieri F, Corbella F, Bertoloni D, Grignani G, et al. The role of surgery in the multimodal treatment of primary gastric non-Hodgkin's lymphomas. A report of 76 cases and review of the literature. Cancer 1990;65:2528-36.
90. Salles G, Herbrecht R, Tilly H, Berger F, Brousse N, Gisselbrecht C, et al. Agressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the group d'Etude des Lymphomes Agressifs. Am J Med 1991;90:77-94.
91. Bozzetti F, Audisio RA, Giardini R, Gennari L. Role of surgery in patients with primary non-Hodgkin's lymphoma ofthe stomach: an old problem revisited. Br J Surg 1993;80:1101-6.
92. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992;102:1628-38.
93. Tedeschi L. Stages I and II non-Hodgkin's lymphoma of the gastrointestinal tract. Retrospective analysis of 79 patients and review of the literature. J Clin Gastroenterol 1994;2:99-104.
94. Ruskoné-Fourmestraux A, Demer A, Lavergne A, Moina T, Brousse N, Audouin J, et al. Multipe lymphomatous polyposis of the gastrointestinal tract: prospective cinicopathologic study of 31 cases. Groupe d'Etude des Lymphomes Digestifs. Gastroenteroogy 1997;112:7-16.